Celemics, Inc. has developed a NGS-based antibody sequencing platform with the aim to overcome key issues of sequencing error, short-read length and high-cost gene synthesis for further characterization. Celemics’ newly developed platform, TrueRepertoire will allow you to sequence scFv or Fab library, analyze the entire variable region and process over 10,000 clones for a single experiment
Celemics continues to support and satisfy various customers around the world. We have started the 'Celemics Customer Interview Series' to highlight the strengths of our company and products. Our first customer is DCGen. Mr. Han-byeol Lee is DCGen's CMO and professor at Seoul National University. During the interview, he discusses DCGen's strong relationship with Celemics and how our kits helped his company. Check out the interview and see why DCGen chose Celemics! www.celemics.com
![[Webinar] Cancer Variant Prioritization and Reporting using StrandOmics thumbnail](https://www.celemics.com/wp-content/uploads/2023/05/webinar-cancer-variant-prioritization-and-reporting-using-strandomics-min.jpg)
[Celemics X Strand Life Sciences Webinar] Celemics and Strand Life Sciences recently announced their partnership to develop a bioinformatics solution that integrates the Celemics bioinformatics pipeline into the StrandOmics environment to enable fast tertiary analysis and reporting of variants from solid tumor genetic tests. The cloud-based, HIPAA-compliant StrandOmics platform relies on a knowledge-base for interpretation of solid tumor and heme variants with over 500 genes, 20,000 variants, 110 FDA drugs and 80,000 clinical trials. StrandOmics has been used to generate clinical reports on ≈10,000 clinical samples tested at Strand’s CAP-accredited genomics lab. It is also used to interpret and report on sequenced data from solid tumor testing for clients in the US and APAC regions. In this webinar our speakers, Dr Urvashi Bahadur and Ernie Kim, will showcase the StrandOmics platform for the interpretation and clinical reporting of solid tumor variants, and additionally discuss the Celemics 405-gene pan cancer solid tumor panel.
Celemics, Inc. has developed a NGS-based antibody sequencing platform with the aim to overcome key issues of sequencing error, short-read length and high-cost gene synthesis for further characterization. Celemics’ newly developed platform, TrueRepertoire will allow you to sequence scFv or Fab library, analyze the entire variable region and process over 10,000 clones for a single experiment
Celemics continues to support and satisfy various customers around the world. We have started the 'Celemics Customer Interview Series' to highlight the strengths of our company and products. Our first customer is DCGen. Mr. Han-byeol Lee is DCGen's CMO and professor at Seoul National University. During the interview, he discusses DCGen's strong relationship with Celemics and how our kits helped his company. Check out the interview and see why DCGen chose Celemics! www.celemics.com
[Celemics X Strand Life Sciences Webinar] Celemics and Strand Life Sciences recently announced their partnership to develop a bioinformatics solution that integrates the Celemics bioinformatics pipeline into the StrandOmics environment to enable fast tertiary analysis and reporting of variants from solid tumor genetic tests. The cloud-based, HIPAA-compliant StrandOmics platform relies on a knowledge-base for interpretation of solid tumor and heme variants with over 500 genes, 20,000 variants, 110 FDA drugs and 80,000 clinical trials. StrandOmics has been used to generate clinical reports on ≈10,000 clinical samples tested at Strand’s CAP-accredited genomics lab. It is also used to interpret and report on sequenced data from solid tumor testing for clients in the US and APAC regions. In this webinar our speakers, Dr Urvashi Bahadur and Ernie Kim, will showcase the StrandOmics platform for the interpretation and clinical reporting of solid tumor variants, and additionally discuss the Celemics 405-gene pan cancer solid tumor panel.
Celemics, Inc. has developed a NGS-based antibody sequencing platform with the aim to overcome key issues of sequencing error, short-read length and high-cost gene synthesis for further characterization. Celemics’ newly developed platform, TrueRepertoire will allow you to sequence scFv or Fab library, analyze the entire variable region and process over 10,000 clones for a single experiment
Celemics continues to support and satisfy various customers around the world. We have started the 'Celemics Customer Interview Series' to highlight the strengths of our company and products. Our first customer is DCGen. Mr. Han-byeol Lee is DCGen's CMO and professor at Seoul National University. During the interview, he discusses DCGen's strong relationship with Celemics and how our kits helped his company. Check out the interview and see why DCGen chose Celemics! www.celemics.com
[Celemics X Strand Life Sciences Webinar] Celemics and Strand Life Sciences recently announced their partnership to develop a bioinformatics solution that integrates the Celemics bioinformatics pipeline into the StrandOmics environment to enable fast tertiary analysis and reporting of variants from solid tumor genetic tests. The cloud-based, HIPAA-compliant StrandOmics platform relies on a knowledge-base for interpretation of solid tumor and heme variants with over 500 genes, 20,000 variants, 110 FDA drugs and 80,000 clinical trials. StrandOmics has been used to generate clinical reports on ≈10,000 clinical samples tested at Strand’s CAP-accredited genomics lab. It is also used to interpret and report on sequenced data from solid tumor testing for clients in the US and APAC regions. In this webinar our speakers, Dr Urvashi Bahadur and Ernie Kim, will showcase the StrandOmics platform for the interpretation and clinical reporting of solid tumor variants, and additionally discuss the Celemics 405-gene pan cancer solid tumor panel.
Celemics, Inc. has developed a NGS-based antibody sequencing platform with the aim to overcome key issues of sequencing error, short-read length and high-cost gene synthesis for further characterization. Celemics’ newly developed platform, TrueRepertoire will allow you to sequence scFv or Fab library, analyze the entire variable region and process over 10,000 clones for a single experiment
Celemics continues to support and satisfy various customers around the world. We have started the 'Celemics Customer Interview Series' to highlight the strengths of our company and products. Our first customer is DCGen. Mr. Han-byeol Lee is DCGen's CMO and professor at Seoul National University. During the interview, he discusses DCGen's strong relationship with Celemics and how our kits helped his company. Check out the interview and see why DCGen chose Celemics! www.celemics.com
[Celemics X Strand Life Sciences Webinar] Celemics and Strand Life Sciences recently announced their partnership to develop a bioinformatics solution that integrates the Celemics bioinformatics pipeline into the StrandOmics environment to enable fast tertiary analysis and reporting of variants from solid tumor genetic tests. The cloud-based, HIPAA-compliant StrandOmics platform relies on a knowledge-base for interpretation of solid tumor and heme variants with over 500 genes, 20,000 variants, 110 FDA drugs and 80,000 clinical trials. StrandOmics has been used to generate clinical reports on ≈10,000 clinical samples tested at Strand’s CAP-accredited genomics lab. It is also used to interpret and report on sequenced data from solid tumor testing for clients in the US and APAC regions. In this webinar our speakers, Dr Urvashi Bahadur and Ernie Kim, will showcase the StrandOmics platform for the interpretation and clinical reporting of solid tumor variants, and additionally discuss the Celemics 405-gene pan cancer solid tumor panel.